ArticleInflammopharmacology2026
Atraric acid mitigates the cognitive and pathological deficits in mice via Aβ
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Alzheimer’s disease (AD) is a neurological disease that leads to cognitive deficits in aged people. There are numerous pathological hallmarks, among them the classical hallmark is β-Amyloid (Aβ), which induces inflammatory events and phagocytic ability of phagocytic cells (such as microglial cells). Until now, the role of atraric acid (AA) in the prevention of AD has not been reported. The study was designed to investigate the contribution of AA to Aβ-induced microglial activation and cognitive deficits. The Aβ-induced AD model was crossed with the AA-treated mice, followed by cognitive and pathological tests. These effects were assessed via western blot, confocal microscopy, Thioflavin-S, Nissl staining, and with behavioral tests (MWM & YM). The cognitive deficit was assessed via the Morris water Maze (MWM) and Y-maze (YM). The Aβ deposition and microglial recruitment were observed by Thioflavin-S and immunohistochemistry. The neuroinflammatory and oxidative stress signaling were identified by western blotting and immunological assays (ROS & LPO), respectively, in brain hippocampal homogenates. Neuronal loss and survival were examined by Nissl staining. The mice treated only with Aβ1−42 i.c.v. shows cognitive and memory deficits, leading to a neurodegenerative condition in mice. In contrast, the intraperitoneal (i.p) delivery of AA (20 mg/kg, for 4 weeks) after the Aβ1−42 injection reduced the amyloid beta (Aβ) burden and glial cells overactivation via inhibiting their surface receptors. Similarly, the AA reduced the oxidative stress by reducing the level of ROS and LPO in brain hippocampal homogenates, as well as enhanced the level of natural endogenous antioxidant proteins and enzymes (Nrf-2 and HO-1) in the Aβ1−42 + AA co-treated group. Moreover, AA retained the neuronal integrity and morphology in the mouse hippocampal brain region, which demonstrates that AA could potentially serve as an anti-inflammatory, antioxidant in progressive neurodegenerative diseases (i.e., AD).
Indexed as
Identifiers
41801600What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.